• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Tuesday 06/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Oncology

  • 5:29 PM

    Aug 19, 2016 OTC Disclosure & News Service – Xenetic Biosciences, Inc. XBIO, (OTCQB: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, announced today that an Investigational New Drug (IND) application for the Company’s product candidate, Virexxa® (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA). This enables Xenetic to initiate a Phase 2 clinical study of Virexxa in conjunction with progestin therapy for the

    Read more
  • Accuray Logo
    3:27 PM

    Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union SUNNYVALE, Calif., Aug. 9, 2016, ARAY /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The next generation hardware and software solutions, together, make up the new Radixact platform, which represents a major step forward in the evolution of Accuray’s

    Read more
  • 3:32 PM

    LEXINGTON, MA— XBIO, (Marketwired – February 12, 2016) – Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics (“Xenetic”) announced today that OPKO Health, Inc. (NYSE: OPK) has acquired an approximate 6.3% interest in Xenetic. Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, “Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science

    Read more
  • 3:44 PM

    NEW YORK, Feb. 10, 2016, DCTH, /PRNewswire/ — Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the Company’s Phase 3 clinical trial:  “A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma” (the FOCUS Trial). The first patient was evaluated and randomized into

    Read more
Public Wire Banner